Verastem Updates Q1 Results, Highlights Phase II/III Oncology Pipeline Progress
VSTM•Verastem Therapeutics published its first-quarter earnings snapshot on May 7, outlining operating highlights and pipeline advancements without disclosing revenue or EPS figures. The update emphasized continued investment in small-molecule oncology candidates, including Phase II and III trials for defactinib and VS-6766.
1. Q1 Earnings Snapshot Released
Verastem Therapeutics released its financial update for the quarter ended March 31, focusing on operational highlights rather than detailed financial metrics. The snapshot highlighted ongoing development of key oncology assets, notably defactinib in Phase III solid tumor trials and VS-6766 in Phase II studies, underscoring the company’s commitment to its pipeline.
